PSY5 Modelling the Cost-Effectiveness of Avacopan in ANTI-Neutrophil Cytoplasmic Antibody Associated Vasculitis Patients: A Conceptual Approach

Journal article

Peer reviewed

M. Glover, A. Ramirez de Arellano Serna, V. Berdunov, A. Meunier, C. Sammon, P. Spearpoint and P. Rutherford

Value in health, Vol.23, pp.S742-S743

12/2020

Files and links (1)

url

https://doi.org/10.1016/j.jval.2020.08.2013View

Published (Version of record) Open

1 Record Views

Title: PSY5 Modelling the Cost-Effectiveness of Avacopan in ANTI-Neutrophil Cytoplasmic Antibody Associated Vasculitis Patients: A Conceptual Approach
Creators: M. Glover - PHMR Ltd, London, UK
A. Ramirez de Arellano Serna - Vifor Pharma, Glattbrugg, ZH, Switzerland
V. Berdunov - PHMR Ltd, London, UK
A. Meunier - PHMR Ltd, London, UK
C. Sammon - PHMR Ltd, London, UK
P. Spearpoint - Vifor Pharma
P. Rutherford - Vifor Pharma
Publication Details: Value in health, Vol.23, pp.S742-S743
Publisher: Elsevier Inc
Publication Date: 12/2020
Identifiers: 991050358502346
Academic Unit: School of Biosciences
Language: English
Resource Type: Journal article